Dose of reality
4 December 2014

A pension fund adviser says the U.S. pharmacy chain is overpaying for the rest of its Swiss-based peer. The complaint is a little confusing, though concerns about risk seem valid. With a big shareholder and activist Jana already on board, the transaction will be tough to derail.